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Abstract. Plasmodium vivax threatens almost 40% of the world’s population, resulting in 132–391 million clinical
infections each year. Most of these cases originate from Southeast Asia and the Western Pacific, although a significant
number also occurs in Africa and South America. Although often regarded as causing a benign and self-limiting
infection, there is increasing evidence that the overall burden, economic impact, and severity of disease from P. vivax
have been underestimated. Malaria control strategies have had limited success and are confounded by the lack of access
to reliable diagnosis, emergence of multidrug resistant isolates, the parasite’s ability to transmit early in the course of
disease and relapse from dormant liver stages at varying time intervals after the initial infection. Progress in reducing the
burden of disease will require improved access to reliable diagnosis and effective treatment of both blood-stage and
latent parasites, and more detailed characterization of the epidemiology, morbidity, and economic impact of vivax
malaria. Without these, vivax malaria will continue to be neglected by ministries of health, policy makers, researchers,
and funding bodies.
INTRODUCTION
The past decade has brought fresh impetus to the fight
against malaria, driven by a growing appreciation of the hu-
manitarian and economic magnitude of the problem and ac-
cess to new funding sources.1 For the most part this resur-
gence of interest has focused on infections with Plasmodium
falciparum, which is associated with the greatest mortality
and, in sub-Saharan Africa, intensity of transmission. In con-
trast P. vivax, the other major species infecting humans, is
usually considered a “benign” infection receiving lower pri-
ority from researchers, policy makers, and funding bodies.
Although the emphasis on P. falciparum is appropriate, the
burden of vivax malaria should not be underappreciated and
exacts a significant toll on almost 40% of the world’s popu-
lation. In this article we examine new evidence highlighting
the magnitude of this burden and discuss major challenges to
achieving a successful control strategy.
EPIDEMIOLOGY
Using national statistics reported by regional offices of the
World Health Organization, the 1999 World Health Report
estimated that there are between 72 and 80 million cases of
malaria due to P. vivax each year with the greatest burden
observed in South and East Asia (52%), Eastern Mediterra-
nean (15%) and South America (13%).2 Recently these sta-
tistics have been challenged by an analysis using a combina-
tion of geographic information systems, malaria epidemiol-
ogy, historical maps, and information on population densities,
environment, and vector limits.3 Revised estimates of the glo-
bal malaria burden were found to be up to 2.5-fold higher
than that derived from national statistics.4 In preliminary
work, Hay and colleagues also found that non-falciparum ma-
laria, predominantly P. vivax, accounts for 25–40% of the
global malaria burden with between 132 and 391 million cases
per year (Table 1). When the population density of areas
endemic for P. vivax is taken into consideration, the number
of people at risk of infection reaches 2.6 billion, slightly
greater than that for P. falciparum.3 Although the debate
over methodologies continues,5,6 it is likely that the true bur-
den of vivax malaria has been grossly underappreciated and is
probably in the region of a quarter of a billion clinical cases a
year.
In South and Southeast Asia, where the majority of vivax
malaria occurs, P. vivax accounts for up to 50% of malaria
cases with prevalence rates between 1% and 6% of the popu-
lation.7–9 The proportional burden of vivax is even greater in
Central and South America, reaching 71–81% of all malaria
cases.10 In eastern and southern Africa only 5% of malaria
infections are attributable to P. vivax, although this still ac-
counts for between 6 and 15 million cases per year.2 The
emergence of chloroquine-resistant P. falciparum has tended
to reduce the proportion of malaria cases due to P. vivax11;
nevertheless the absolute numbers of P. vivax remain high.
Conversely, where successful malaria control strategies have
been used the ratio of P. falciparum to P. vivax infections has
fallen.12
In most areas the burden of disease is greatest in young
children and infants with immunity usually developing by 10
to 15 years of age.13 In a longitudinal study from Thailand,
incidence rates varied from over 800 per 100 person-years in
children under 5 years to 200 per 100 person-years in older
adults. In these low-transmission settings premunition and
asymptomatic carriage occur,14 although overall 82% of pa-
tients with P. vivax parasitaemia were still found to be symp-
tomatic.7 Extrapolating this figure to the estimated total num-
ber of P. vivax infections presented in Table 1 suggests that
there are between 106 and 313 million clinical cases of vivax
malaria each year.
PATHOBIOLOGY
Compared with P. falciparum, P. vivax has a slightly longer
incubation period (12 days to several months), a similar eryth-
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rocytic cycle (42-48 hours), and produces fewer merozoites
per schizont.15 It is generally believed that P. vivax merozo-
ites require a single cell receptor, the Duffy antigen, to invade
host erythrocytes. Humans lacking this antigen are not sus-
ceptible to infection, explaining why P. vivax is largely absent
from West Africa, a highly malarious region where the Duffy
negative blood group is ubiquitous.16 Recently this paradigm
has been challenged by observations in East Africa, demon-
strating P. vivax transmission in a population found to be
Duffy antigen negative, although further studies are needed
to elucidate the epidemiology.17 P. vivax is further limited by
its apparent preference for invading young red cells, whereas
P. falciparum invades a broader range of erythrocyte ages.18
This selective preference for red cell invasion is an important
factor limiting the growth of P. vivax both in vitro and in vivo.
The latter was noted over 100 years ago by Ross who com-
mented upon the lower levels of parasitemia observed in fe-
brile patients with benign tertian malaria (P. vivax) compared
with those with malignant tertian (P. falciparum).19 P. vivax is
capable of inducing fever at levels of parasitemia lower than
those causing fever in P. falciparum infection. In western
Thailand, a region of low endemicity, the pyrogenic density
was 180 parasites/l, compared with 1000 parasites/l ob-
served in P. falciparum infection.7 These estimates are similar
to those observed in volunteers and malariotherapy pa-
tients.20 In keeping with this the host inflammatory response
is activated to a greater extent during infections with P. vivax,
with plasma levels of fever-inducing cytokines such as TNF-
being higher in vivax malaria compared with P. falciparum
infections with similar parasitemia.21,22
In addition to lower peripheral parasitemias, patients with
P. vivax infections also tend to present with all parasite stages
visible on the peripheral blood film. In contrast the late stages
of P. falciparum are usually absent or present in low numbers,
reflecting cytoadherence in the postcapillary venules. The lat-
ter is fundamental to the etiology of severe and placental
malaria in P. falciparum infections.23 In contrast P. vivax-
infected red blood cells become increasingly more deform-
able as they mature24 and are usually considered not to cy-
toadhere or sequester in the microvasculature. These charac-
teristics underlie the reason why severe pathology in vivax
infections is much less common than with P. falciparum in-
fection. Interestingly recent studies have challenged this para-
digm by suggesting that P. vivax-infected red cells may se-
quester in organs such as the lung.25
One of the most important differences between the plas-
modial species infecting humans lies in the ability of P. vivax
and P. ovale to relapse after the cure of the original infection.
A proportion of sporozoites do not undergo immediate de-
velopment in the invaded hepatocytes. Instead they remain
dormant in the liver, as hypnozoites, for prolonged periods of
time before developing and causing recurrent infection. P.
vivax strains from different geographic areas display widely
different relapse patterns, reflecting evolutionary adaptation
to local environmental conditions that optimize transmission
potential of the parasite. Strains from tropical areas are char-
acterized by early primary infection followed by frequent (10–
14) relapses 3–6 weeks apart.26 Whereas in temperate areas
primary infection tends to occur later with intervals up to 1
year and fewer and later relapses to overcome prolonged pe-
riods of the year when transmission to the mosquito vector is
unfavorable.27 The ability to relapse renders P. vivax resilient
to eradication from both the human host and the environ-
ment.
CLINICAL MANIFESTATIONS
Clinical disease is associated with chills, vomiting, malaise,
headache, fever, and myalgia. These symptoms are non-
specific and cannot be distinguished reliably from other fe-
brile illnesses or other malarias.7 High fever and rigors are
more common in vivax than falciparum malaria, reflecting
synchronicity of schizont rupture. The classic paroxysms of
fever lasting 4–8 hours and occurring with 48–56 hour peri-
odicity, take several asexual cycles to develop in primary in-
fections, although relapses often start synchronously with
rigors.28 Plasmodium vivax has a reputation as a benign in-
fection, when compared with the severe manifestations fre-
quently observed with untreated P. falciparum. However, in
the pre-antibiotic era vivax malaria resulted in a chronic de-
bilitating febrile illness that could last for years and was as-
sociated with hypoproteinemia and edema and dramatic
weight loss akin to kwashiorkor.26 Even today with access to
effective antimalarials, severe and fatal infections can occur
with P. vivax. It has long been recognized that splenic rupture
is a life-threatening, though rare, complication.29 More re-
cently P. vivax has been shown to cause severe anemia, res-
piratory distress, malnutrition,30 and possibly coma.31–33
In areas endemic for P. vivax, prevalence usually reaches a
peak in young infants and children. In impoverished commu-
nities, anemia from malnutrition, worm infestations and fal-
ciparum malaria can be near-universal in this age group. Re-
current hemolysis (of both parasitized and non-parasitized
TABLE 1
Estimates of population at risk of P. vivax and number of clinical cases per year (in million)
WHO Regional Offices
Population at risk of P. vivax infection (millions) Number of P. vivax infections per year (millions)
Mendis2 Guerra3 Mendis2 Hay4*
Africa AFRO 550 50 6–15 —
America AMRO 87.7 78 11.1 10–28
East Mediterranean EMRO 64.6 211 11.7 11–34
Europe EURO — 20 — 1.4–4.2
Central Asia 8.5 — 0.17 —
Sea East Asia SEARO 1,284 1,347 42.1 90–248
Western Pacific WPRO 89 20–77
Total 1,995 2,596 71–80 132–391
* Adapted from estimates on non-falciparum malaria, assuming that P. vivax constitutes the 90% of these infections.
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red cells)34 and dyserythropoesis from relapsing vivax malaria
exacerbate this multifactorial anemia. Although most studies
have not quantified the proportion attributable to vivax ma-
laria, in some areas P. vivax infections are likely to be the
most important determinant of anemia in infants. A case in
point comes from southern Papua, Indonesia where almost
38% of patients hospitalized with malaria are anemic (Hb < 7
g/dl). In this region, 40% of severe anemia (Hb < 5g/dl) in
infants can be attributed to infections with P. vivax, a rate
almost 3-fold higher than that for P. falciparum.8 Similar find-
ings in Venezuela also suggest that anemia may be more se-
vere and frequent in P. vivax infections than in P. falci-
parum.35 When compounded by even mild respiratory dys-
function and malnutrition, such degrees of anemia are likely
to be an important contributor to morbidity, hospital stay,
and even mortality.30
Pregnant women are particularly vulnerable to malaria.
Plasmodium falciparum sequesters in the placenta resulting in
pathologic changes and compromise of materno-fetal trans-
port, resulting in adverse outcomes in both mother and baby.
The burden of P. vivax malaria in pregnancy is less well de-
scribed. P. vivax does not appear to sequester in the pla-
centa36 and is associated with less pronounced histologic
changes in the placenta, the main process being increased
hemozoin deposition.36 However P. vivax may still exert an
adverse effect on the fetus through maternal anemia and the
induction of a strong local inflammatory response, both of
which interfere with utero-placental hemodynamics.37 Clini-
cal findings from Thailand and India have shown that vivax
malaria during pregnancy causes maternal anemia and a sig-
nificant reduction in mean birthweight (about 110 g), which is
about 60% of that observed with falciparum malaria38,39; this
almost certainly contributes to infant mortality. Interestingly,
in contrast with falciparum malaria, the birthweight reduction
is greater in multigravidae than primigravidae.
There have now been at least 18 case reports of non-
cardiogenic pulmonary edema/acute lung injury in vivax ma-
laria, almost all of which have excluded concurrent infection
with P. falciparum.25,40,41 All of the cases developed after
commencement of antimalarial chemotherapy, raising the
possibility of a pulmonary inflammatory response to parasite
killing.42 The possible sequestration of P. vivax in the pulmo-
nary microvasculature25 may target this inflammatory re-
sponse to the lung. Although further studies are needed, these
findings and the observation that over 50% of patients with
vivax malaria present with cough25,42 suggest that, as with P.
falciparum,43 there may be an important overlap between the
clinical features of acute respiratory infections and acute
vivax malaria. There have also been several reports of coma
associated with vivax malaria31–33 though most have not ex-
cluded concurrent infection with P. falciparum or other
pathogens with central nervous system manifestations.
These reports of severe manifestations after vivax malaria
challenge the usual perception of P. vivax as a benign infec-
tion. The spectrum of disease caused by P. vivax in Papua
New Guinea and Papua, Indonesia, appear particularly bad;
indeed in southern Papua 16% of all cases of severe malaria
admitted to hospital were attributable to P. vivax.8 Reports
from India and Sri Lanka also highlight the broad range of
pathology associated with P. vivax.2,33 However, these rates
may not necessarily be extrapolated to other endemic areas.
Differences in parasite virulence, host susceptibility, age of
exposure as well as parasite factors such as antimalarial drug
resistance may play a crucial role in modulating the clinical
presentation. Alternatively the spectrum of disease in other
areas may simply be underreported, particularly if severe pa-
thology is mistakenly attributed to co-infection or misdiagno-
sis in speciation.
MIXED INFECTIONS
In regions where P. falciparum and P. vivax coexist, mixed-
species infections are common and yet rarely reported. Sur-
veys usually report rates less than 2% and yet careful clinical
studies record rates up to 30% and this figure is even higher
when PCR detection methods are used.44 Concurrent infec-
tions with different plasmodium species may have important
implications on the host response and development of cross-
species immunity.45 Indeed in Thailand where this has been
particularly studied, mixed infections with P. vivax appear to
attenuate the severity of disease with P. falciparum reducing
the risk of severe malaria,46 decreasing the risk of treatment
failure,47 lowering gametocyte carriage,48 and reducing the
prevalence of anemia.49 However in higher-transmission ar-
eas and areas of emerging drug resistance, the additive bur-
den of severe malarial anemia and maternal malaria has not
been addressed in detail. The potential for P. vivax to attenu-
ate falciparum malaria requires further characterization, and
has significant implications for vivax-only vaccination strate-
gies, and the deployment of drugs such as chloroquine, which
have lost efficacy against P. falciparum but still retain it
against P. vivax.
SOCIO-ECONOMIC BURDEN
The appreciation of the socio-economic burden of malaria
has risen over the past decade and has been a major factor in
raising its global profile and the funds dedicated to combating
the disease. Falciparum malaria alone is estimated to have
reduced the Gross Domestic Product of 31 African countries
by almost 10%.50 Although neglected, a number of observa-
tions suggest that P. vivax is also likely to exert a considerable
economic toll. The incidence of P. vivax varies between re-
gions, and age groups, with P. vivax relapses occurring in
20–80% of patients.27 This ensures that even in low-trans-
mission areas, up to 20% of the population can have a symp-
tomatic infection each year with a cumulative experience of
10–30 episodes of malaria during a lifetime.2
The socio-economic burden of P. vivax infection is not
known. Based on the estimated number of clinical episodes
per year (106–313 million), assuming full treatment coverage
with drug costs of $0.1 per course of chloroquine and non-
drug treatment costs of $8.3,51 the direct cost of treatment is
between US$0.9 and 2.7 billion per year. Because each symp-
tomatic infection is associated with at least 3 days of absence
from school or work (unpublished data), the overall global
cost of P. vivax infection to the individual in terms of lost
productivity (assuming a daily wage of US$1.5 per day),
healthcare costs and transport to clinics can be conservatively
estimated as being between US$1.4 and 4.0 billion per year.
These immediate costs are likely to be augmented by re-
current P. vivax infections in children. Longitudinal studies
from Sri Lanka suggest that repeated attacks of malaria have
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an adverse impact on the school performance of children.52,53
Intuitively, recurrent vivax malaria will also result in anemia,
malnutrition, growth retardation, stunting of development,
and impaired economic productivity later in life, though de-
tailed studies are lacking.
The burden of vivax malaria is felt not only at the indi-
vidual level but also by healthcare providers. In many parts of
Asia and South America, where P. vivax accounts for more
than half of the cases of malaria, institutional healthcare costs
are appreciably higher due to high rates of clinic attendance
and hospitalization. In Thailand and Indonesia almost 30% of
patients hospitalized with malaria are associated with pure P.
vivax infections.8,12 Again further studies are needed to quan-
tify these costs more precisely.
DIAGNOSIS AND MANAGEMENT OF
VIVAX MALARIA
Although microscopy remains the mainstay of diagnosis of
vivax malaria, lack of access to good quality microscopy ser-
vices in many endemic regions limits the reliability of diag-
nosis (as well as contributes to the underestimation of cases).
HRP-2-based rapid diagnostic tests (RDTs) are usually sen-
sitive for the diagnosis of P. falciparum, although aldolase-
based and parasite lactic dehydrogenase-based RDTs have
suboptimal sensitivity for P. vivax,54,55 limiting the utility of
RDTs for vivax diagnosis.56
Chloroquine has been the mainstay of treatment of acute
vivax malaria for more than 50 years with dosing recommen-
dations generally similar to those for P. falciparum (25 mg
base/kg up to 1.55 g, given in 3 or 4 doses over 3 days). After
eradication of the asexual stages of P. vivax from the periph-
eral blood, patients are at risk of relapse from the dormant
liver stage. In equatorial regions such relapses occur in 20–
80% of patients.27,57 Chloroquine has potent activity against
asexual stages, but no activity against hypnozoites. However,
its long terminal elimination ensures that plasma concentra-
tions of chloroquine are sustained above the minimum inhi-
bition concentration for at least 28 days and thus are capable
of suppressing the first relapse, which in tropical zones occurs
at about 21 days.58 The prevention of further relapses neces-
sitates eradication of the dormant liver stages; however, only
one antimalarial agent is registered with such activity, the
8-aminoquinoline primaquine. The standard recommenda-
tion for radical cure of P. vivax has been 15 mg primaquine
daily over 14 days.27 In some areas, particularly the Indian
subcontinent, 5-day courses are recommended despite there
being no evidence that they prevent relapse. The efficacy of
the 14 day regimen varies considerably with relative resis-
tance documented in Oceania and parts of Asia.59,60 Several
unsubstantiated reports also suggest that primaquine efficacy
may be waning elsewhere.27 The problem is particularly bad
in Papua and Papua New Guinea where P. vivax demon-
strates marked tolerance to primaquine.61,62 Higher doses or
longer courses have been advocated and may be more effec-
tive63; however, in practice, long courses of unsupervised
therapy are rarely adhered to and thus likely to be ineffective.
Furthermore, primaquine is contraindicated in infancy and
pregnancy and causes hemolysis in G6PD-deficient individu-
als. In endemic settings, shorter alternatives are needed ur-
gently. Short-course tafenoquine has potential,64 but is not
registered and concerns about its prolonged hemolytic poten-
tial have tempered enthusiasm for its use in endemic areas
where routine screening for G6PD deficiency is not possible.
CHLOROQUINE RESISTANCE (CQR)
Whereas chloroquine-resistant P. falciparum was first
documented over 50 years ago, drug-resistant strains of P.
vivax have taken much longer to emerge. This may reflect
species differences in the underlying molecular mechanisms
of resistance or lower selection pressure because of differ-
ences in the biology of gametocytogenesis. Gametocytogen-
esis in P. falciparum occurs after the appearance of symptoms
and is refractory to schizontocidal drugs, thus favoring the
transmission of resistant genotypes. In contrast gametocytes
occur earlier in P. vivax compared with P. falciparum infec-
tions and are eliminated rapidly by schizontocidal agents, en-
suring early transmission prior to selection.
The first case of CQR P. vivax (CQRPV) was reported in
1989 from Papua New Guinea65 and was soon followed by
reports from northern Papua, Indonesia.66–68 By 1995, in
some parts of Papua almost all patients with vivax malaria
treated with chloroquine monotherapy failed therapy within
28 days.69 Other studies subsequently confirmed a high preva-
lence of chloroquine resistance elsewhere in Papua,70 and
other parts of Indonesia.71,72 Sporadic cases have also been
reported from Burma,73 South America,74,75 Vietnam,76 and
Turkey77; see Figure 1. In contrast, chloroquine mostly re-
tains its efficacy against P. vivax in Thailand and India.57,78,79
Despite these reports, the global prevalence of CQRPV is
still poorly defined. In a recent systematic review only 11%
(47/435) of published antimalarial drug trials between 1966
and 2002 addressed the efficacy of antimalarial drugs against
P. vivax.80 This reflects both the inherent difficulties associ-
ated with the in vivo test for relapsing malarias and, in the
absence of any empirical evidence, the belief that established
protocols continue to be effective. The latter was a major
reason why policies were so slow to respond to the collapse of
chloroquine efficacy against P. falciparum in sub-Saharan Af-
rica a decade ago. The WHO 1999 Guidelines recommended
a 14-day follow-up for the in vivo diagnosis of CQR P. vivax
and such a short duration is incapable of detecting early de-
cline in antimalarial therapeutic efficacy.81 The 2005 WHO
guidelines have extended follow-up to 28 days, which im-
proves the sensitivity of the test, but at the expense of in-
creasing confounding results from reinfection and relapse.
Parasite genotyping has been useful in discriminating reinfec-
tion and recrudescence in P. falciparum, but the use of a
similar strategy in P. vivax is more complex.82 Relapses can
occur either from the primary infection (in which case they
are identical to recrudescent infections) or from a previous
infection (in which case they maybe be misclassified as a re-
infections); allocating a treatment outcome to a recurrent
parasitemia is therefore not possible. In practice, recurrent
infections occurring within 28 days of supervised chloroquine
administration will be growing in the presence of chloroquine
concentrations normally considered above those required to
inhibit parasite multiplication and thus can be considered re-
sistant.83 Monitoring the uncorrected cure rate at day 28 is
therefore a reasonable indicator of declining chloroquine ef-
ficacy, which can be confirmed by analysis of whole blood
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chloroquine concentrations to ensure adequate drug absorp-
tion.
In vitro susceptibility assays provide another means of as-
sessing drug susceptibility of Plasmodium spp. free from the
confounders of host immunity, relapse, and reinfection. Al-
though these tests have been used in P. falciparum for more
than 30 years, their application in P. vivax has been more
difficult to develop because of the inability to culture the
parasite through schizogeny in an ex-vivo assay. Recently sev-
eral groups from Thailand, where P. vivax responds well to
chloroquine, have reported successful adaptation of schizont
maturation assays deriving IC50 values for P. vivax to chlo-
roquine in the range of 30–120 nM.79,84,85 Preliminary studies
from Papua, Indonesia, where clinical studies have estab-
lished the presence of high-grade CQR, demonstrate that
chloroquine susceptibility of P. vivax is 5-fold lower than that
reported in Thailand.86 These findings suggest that in vitro
testing may prove useful in monitoring for the emergence of
resistance.
The other important tool for monitoring antimalarial drug
resistance is tracking the prevalence of genetic markers of
resistance. However, our current understanding of the mo-
lecular mechanisms of CQR in P. vivax is limited and pre-
liminary studies suggest that resistance mechanisms may be
different from that seen in P. falciparum.87 Renewed interest
in identifying putative molecular markers of CQRPV has
been stimulated by the recent completion of the vivax ge-
nome project.
MANAGEMENT OF RESISTANT P. VIVAX.
In vivo drug studies on strains of P. vivax sensitive to chlo-
roquine have demonstrated the efficacy of artemisinin deriva-
tives, mefloquine, quinine, and halofantrine88; however, few
studies have addressed suitable treatment regimens for CQR
vivax malaria.83 P. vivax has previously been regarded as in-
trinsically resistant to antifols. It is not; but resistance devel-
ops readily,68,89 through the sequential acquisition of muta-
tions in Pvdhfr.68,90,91 The prevalence of antifol resistance is
similar to that of P. falciparum with high levels of resistance
in much of Southeast Asia92 (Laos is a notable exception) and
lesser degrees of resistance in the Indian subcontinent.
In Indonesia the efficacy of amodiaquine is superior to that
of chloroquine, but in regions where high levels of CQR pre-
dominate, day 28 failure rates exceed 25%, suggesting amo-
diaquine monotherapy is not a suitable alternative once high-
grade resistance has been reached.93 Better success in the
same region has been obtained with mefloquine and halofan-
trine, which retain almost 100% cure rates by day 28.94,95
Atovaquone–proguanil plus primaquine also showed excel-
lent efficacy against CQR P. vivax96; however, the high cost of
this regimen (∼US$40) virtually precludes its use in endemic
communities.
The artemisinin derivatives are highly potent antimalarials
and are even more active against P. vivax than P. falci-
parum.97 Artemisinin combination therapy (ACT) is now
widely advocated for the management of P. falciparum infec-
tions. In practice only a minority of infections has correct
species identification prior to treatment and therefore in Asia
and South America it is highly likely that other species will
also be treated with ACT. Despite this, only 3 studies have
addressed the efficacy of these combinations against P. vivax.
In the first, a 3-day course of artesunate plus sulfadoxine-
pyrimethamine resulted in a recurrence rate of 10.5% by day
28.68 In 2 subsequent studies of patients with pure P. vivax
infections, recurrence rates by day 28 were significantly
higher after artemether–lumefantrine (23%) and amodi-
aquine–artesunate (12%) than after dihydroartemisinin pi-
peraquine (3.6%).93,98 None of these antimalarial drugs have
any efficacy on the hypnozoite stages of P. vivax and hence
the difference in cure rates is likely to be a consequence of
the difference between the terminal elimination half life of
lumefantrine (∼4 days), amodiaquine (18 days) and that of
piperaquine (28–35 days). Piperaquine, like chloroquine,
suppresses the first relapse whereas lumefantrine and amodi-
aquine do not. In areas where primaquine cannot be super-
FIGURE 1. Published reports of treatment failure after chloroquine monotherapy (25 mg base/kg up to 1.55 g over 3 days) for P. vivax
infections. Large white stars clinical trials of chloroquine monotherapy with > 10% recurrence rate by day 28; small black stars case series
with < 5 recurrences before day 28 (with or without chloroquine plasma drug levels); black circles clinical trials after 2000, with no recurrences
by day 28.
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vised, such post-treatment prophylaxis afforded by drugs with
long half lives will not prevent subsequent relapses, but will
provide the only practical means currently available of delay-
ing the timing of clinical illness from these relapses. The latter
affords patients a longer period free from symptomatic ma-
laria, decreases the risk of anemia and reduces significantly
gametocyte carriage and thus the transmission potential to
the mosquito vector.93 Although longitudinal studies are
needed to confirm these findings, when choosing an alterna-
tive to chloroquine in communities where CQR vivax malaria
is endemic, the relevance of post-treatment prophylaxis
should not be overlooked.
CONTROL OF VIVAX MALARIA
Malaria control programs generally focus on providing
good vector control, early diagnosis, and access to effective
antimalarial regimens, preferably with anti-gametocyte activ-
ity to reduce transmission. In areas where both species are
present, ACT-treatment–based programs have greater impact
on P. falciparum than P. vivax.12,99 Intensive eradication pro-
grams were successful in Europe, US, Australia, and in the
1940s–1960s both P. falciparum and P. vivax were almost
eradicated from India with intensive DDT-based vector con-
trol and effective chloroquine chemotherapy.100 The subse-
quent abandonment of DDT-based vector control led to a
resurgence of both species in South Asia. Control measures
remain limited in most areas of Asia, South America, and
temperate regions of the middle and Far East and are com-
pounded by political instability in central Asia where there
has been a resurgence of vivax malaria. This lack of progress
is of particular concern in view of the availability of both
DDT and chloroquine, the latter remaining inexpensive and
effective against vivax malaria in most areas. Chloroquine-
resistant strains of the parasite are already firmly established
in Papua New Guinea and eastern Indonesia and as they
spread further afield will impact significantly on the current
control program.
The drive to tackle P. vivax is very much dependent upon
the perception of the threat that it poses. The latter has been
hampered by an under-appreciation of the morbidity and
mortality from vivax malaria, and the paucity of literature
focused on this species. A crucial step in recruiting the inter-
est of ministries of health, policy makers, researchers, and
funding bodies will be the detailed characterization of the
clinical epidemiology and economic burden of P. vivax in
different geographical areas. From here our knowledge and
experience with P. falciparum provides a useful framework
with which to tackle perhaps the greater challenges that we
face in controlling P. vivax.
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